MaxCyte, Inc. Appointment of Joint Corporate Broker (8822B)
June 12 2019 - 1:00AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 8822B
MaxCyte, Inc.
12 June 2019
MaxCyte, Inc.
("MaxCyte" or the "Company")
Appointment of Joint Corporate Broker
Gaithersburg, Maryland - 12 JUNE 2019: MaxCyte (LSE: MXCT,
MXCS), the global clinical-stage, cell-based therapies and life
sciences company, announces the appointment of Numis as the
Company's joint Corporate Broker with immediate effect. Panmure
Gordon will continue to act as the Company's Nominated Adviser and
joint Corporate Broker.
About MaxCyte
MaxCyte is a global clinical-stage cell-based therapies and life
sciences company applying its proprietary cell engineering platform
to deliver the advances of cell-based therapy to patients with high
unmet medical needs. MaxCyte is developing novel CARMA(TM)
therapies for its own pipeline, with its first drug candidate in a
Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary
therapeutic platform for autologous cell therapy for the treatment
of solid cancers. In addition, through its life sciences business,
MaxCyte leverages its Flow Electroporation(R) Technology to enable
its biopharmaceutical partners to advance the development of
innovative medicines, particularly in cell therapy. MaxCyte has
placed its flow electroporation instruments worldwide, with all of
the top ten global biopharmaceutical companies. The Company now has
more than 70 partnered programme licenses in cell therapy with more
than 35 licensed for clinical use, including four announced
commercial licenses covering potentially more than 30 products with
aggregate potential milestones of more than $250m plus significant
additional potential milestones from the multi-drug commercial
agreement with Kite announced 1 March 2019. With its robust
delivery technology platform, MaxCyte helps its partners to unlock
the full potential of their products. For more information, visit
www.maxcyte.com.
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer +1 301 944 1660
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
James Stearns +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith +44 (0)20 7260 1000
Financial PR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
Sukaina Virji
--------------------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
APPFBMFTMBABBAL
(END) Dow Jones Newswires
June 12, 2019 02:00 ET (06:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2024 to Jun 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2023 to Jun 2024